Exhibit 99.1




Intercept Pharmaceuticals Reports 2015 Financial Results and Provides Business Update


NEW YORK, February 23, 2016

-- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided other general business updates. Intercept will hold a conference call and audio webcast today at 8:00 a.m. Eastern Time to review this information with conference call details provided below.


Summary of Program Progress


·Primary Biliary Cirrhosis (recently renamed Primary Biliary Cholangitis [PBC]) Program

oCompleted NDA/MAA filings for PBC June 2015

oPriority Review granted by FDA August 2015


·Nonalcoholic Steatohepatitis (NASH) Program

oBreakthrough therapy designation granted from FDA for OCA in NASH with liver fibrosis in January 2015
oREGENERATE Phase 3 trial in non-cirrhotic NASH patients with liver fibrosis initiated September 2015
oCONTROL Phase 2 statin trial initiated December 2015


·Primary Sclerosing Cholangitis (PSC) Program

oAESOP Phase 2 trial continued enrollment


·Biliary Atresia Program

oCARE Phase 2 trial initiated October 2015


·INT-767 Program

oPhase 1 trial initiated November 2015


Planned 2016 Milestones


·PBC Program

oScheduled FDA Advisory Committee meeting April 7, 2016

oPDUFA date May 29, 2016 with planned US launch in June if NDA is approved

oAnticipated EU marketing authorization application decision in late 2016


·NASH Program

oContinued enrollment of REGENERATE and CONTROL trials

oPlanning of NASH cirrhosis and non-invasive technology trials


·INT-767 Program

oCompletion of Phase 1 trial and planning of Phase 2 trial


The following information was filed by Intercept Pharmaceuticals, Inc. (ICPT) on Tuesday, February 23, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Intercept Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Intercept Pharmaceuticals, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Log in with your credentials


Forgot your details?

Create Account